Keith Murphy

Corporate Headquarters

440 Stevens Avenue, Suite 200 Solana Beach, CA 92075
Tel: (858) 224-1000

Find Us On

Keith Murphy

Keith Murphy is currently CEO and Chairman of Viscient Bio, Inc., and a serial entrepreneur and investor in biotech.  Prior to co-founding Viscient Biosciences, Mr. Murphy founded Organovo in 2007 and led all company operations until 2017.  He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships  Prior to Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($4B+ annual sales).  Prior to Amgen, he played a key role at Alkermes (NASDAQ:ALKS) in the successful development of once-monthly human growth hormone (hGH) in partnership with Genentech.  He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.  Mr. Murphy serves on the Boards of Directors of the California Life Sciences Association, the state’s life science industry public policy, advocacy and business leadership organization, and Kintara Therapeutics (NASDAQ: KTRA)